Recommendations on the inclusion of people with disabilities in eye care made by CBM's Medical Eye Care Advisory Group as a result of
a meeting in Hydrabad, India, in 2012.
Lessons learned in Burkina Faso, Ethiopia & Mozambique 2009 - 2011
Workshop on PHC Revitalisation in Nepal, April 5-6, 2010
Part of the CBM Prevention Toolkit on “How to Improve the Health and Development of your Child”
Contact No 175 - October December 2001
…voices of persons with disabilities - Part 1
CBM strategy overview paper on preventing physical impairment in childhood.
The Liliane Foundation in collaboration with Enablement has been running a pilot focusing on children with neurodevelopmental disorders in 4 African countries called: Support Tools Enabling Parents (STEP). We can share details of the pilot including the evaluation report; report of a research proje...ct (with baseline and end line study); tools etc.
Write an Email to: h.cornielje@enablement.nl
more
Review of disability issues and rehabilitation services in 29 african countries.
Si tienes tos, puedes tener una enfermedad respiratoria:
Puede ser COVID-19, si es de aparición rápida, acompañada de tos seca, malestar general, fiebre y dificultad para respirar.
Puede ser TB, si se presenta como una tos de dos o más semanas de duración, y está acompañada de expectora...ción.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
You can find manuals, guidelines and information in our Section Radiological & Nuclear Hazards in the SPECIFIC HAZARDS TOOLBOX
You can find manuals, guidelines and information in our Section Chemical Hazards in the SPECIFIC HAZARDS TOOLBOX
Malgré les progrès récents vers la mise au point d’un traitement hautement efficace et abordable contre le virus de l’hépatite C, beaucoup de personnes infectées par ce virus ne connaissent pas leur statut. L’Organisation mondiale de la Santé (OMS) estime qu’en 2019, 58 millions ...de personnes à travers le monde étaient atteintes d’une infection chronique par le virus de l’hépatite C, et qu’à peine 21 % d’entre elles avaient été diagnostiquées. Le défaut de sensibilisation, l’accès limité aux services de dépistage et de traitement, la stigmatisation, la discrimination et d’autres obstacles structurels contribuent au faible taux d’utilisation des services de dépistage du virus de l’hépatite C.
more